KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Non-Current Deffered Revenue: 2020-2024

Historic Non-Current Deffered Revenue for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $5.7 million.

  • AbCellera Biologics' Non-Current Deffered Revenue fell 27.78% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year decrease of 27.78%. This contributed to the annual value of $5.7 million for FY2024, which is 30.45% down from last year.
  • Per AbCellera Biologics' latest filing, its Non-Current Deffered Revenue stood at $5.7 million for FY2024, which was down 30.45% from $8.2 million recorded in FY2023.
  • AbCellera Biologics' 5-year Non-Current Deffered Revenue high stood at $27.4 million for FY2021, and its period low was $5.7 million during FY2024.
  • Over the past 3 years, AbCellera Biologics' median Non-Current Deffered Revenue value was $8.2 million (recorded in 2023), while the average stood at $11.1 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first climbed by 5.85% in 2021, then slumped by 58.01% in 2023.
  • Yearly analysis of 5 years shows AbCellera Biologics' Non-Current Deffered Revenue stood at $25.9 million in 2020, then rose by 5.85% to $27.4 million in 2021, then fell by 28.80% to $19.5 million in 2022, then plummeted by 58.01% to $8.2 million in 2023, then slumped by 30.45% to $5.7 million in 2024.